

37. A method of (a) treating diseases or disorders characterized by undesirable excessive neovascularization or vascular permeability in a mammal or (b) treating a dysfunctional state characterized by excessive activation of a receptor for a VEGF-related protein (VRP), in a mammal,
- comprising administering to said mammal an effective amount of a monoclonal antibody which binds to an extracellular domain of a Flt4 receptor and neutralizes a biological activity of a VRP containing at least 265 amino acids.
38. The method of claim 37, wherein the biological activity of the VRP is promoting neovascularization or vascular permeability or vascular endothelial cell growth in a mammal.
39. The method of claim 37, wherein the monoclonal antibody binds to the N-terminal portion from residues -20 through 137, inclusive, or from residues 1 through 137, inclusive, of the amino acid sequence shown in Figure 1.

REMARKS

Claims 32-39 are now pending in this application. The new claims are supported by original claim 23 and the specification as filed. No new matter is believed to have been introduced.

This application is now believed to be in condition for examination on the merits. The Examiner is invited to telephone the undersigned at (650) 225-7467 if deemed helpful to clarify and advance prosecution.

Respectfully submitted,

GENENTECH, INC.

Date: May 17, 1999

By: 

Timothy R. Schwartz, Ph.D.

Reg. No. 32,171

1 DNA Way  
So. San Francisco, CA 94080-4990  
Phone: (650) 225-7467  
Fax: (650) 952-9881

A